Rosiglitazone in the treatment of type 2 diabetes mellitus: A critical review

Clinical Therapeutics

Volumn 22, Issue 10, 2000, Pages 1151-1168

  Malinowski, Jennifer M ^a   Bolesta, Scott ^b  

^a WILKES UNIVERSITY   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Glycemic control; Rosiglitazone; Type 2 diabetes mellitus

Indexed keywords

AMIODARONE; CIMETIDINE; FLUCONAZOLE; FLUVOXAMINE; GLIBENCLAMIDE; GLYCOSYLATED HEMOGLOBIN; ISONIAZID; METFORMIN; OMEPRAZOLE; PHENOBARBITAL; PRIMIDONE; RIFAMPICIN; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; ZAFIRLUKAST;

ADULT; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INJURY; INSULIN RELEASE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

EID: 0033744396     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)83060-X     Document Type: Article

References (47)

1. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994
2. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes
3. Clinical practice recommendations 2000
4. Thiazolidinediones in the treatment of insulin resistance and type II diabetes
5. Consensus Development Conference on Insulin Resistance
6. Identification of high affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator activated receptor gamma
7. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor
8. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)
9. The short- and long-term effects of tumor necrosis factor-alpha and BRL 49653 on peroxisome proliferator activated receptor (PPAR) gamma-2 gene expression and other adipocyte genes
10. BRL 49653 blocks the lipolytic actions of tumor necrosis factor-alpha: A potential new insulin-sensitizing mechanism for thiazolidinediones
11. Systemic exposure to rosiglitazone is unaltered by food
12. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone
13. A study of the effect of age on the pharmacokinetics of BRL 49653C in healthy volunteers
14. Rosiglitazone does not increase risk of alcohol induced hypoglycemia in diet treated type 2 diabetics
15. Effect of renal impairment on the pharmacokinetics of rosiglitazone
16. Pharmacokinetics of rosiglitazone are unaltered in hemodialysis patients
17. Effect of hepatic impairment on the pharmacokinetics of rosiglitazone
18. Rosiglitazone once or twice daily improves glycemic control in patients with type 2 diabetes
19. Rosiglitazone (BRL49653) monotherapy has significant glucose lowering effect in type 2 diabetic patients
20. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes
21. Rosiglitazone is superior to glyburide in reducing fasting plasma glucose after 1 year of treatment in type 2 diabetic patients
22. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial
23. Rosiglitazone improves glycemic control in poorly controlled, insulin-treated type 2 diabetes
24. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients
25. Hepatic failure in a patient taking rosiglitazone
26. Rosiglitazone is safe and well tolerated as monotherapy or combination therapy in patients with type 2 diabetes mellitus
27. Rosiglitazone therapy is not associated with hepatotoxicity
28. Rosiglitazone is effective and well tolerated in patients ≥65 years with type 2 diabetes
29. Thiazolidinediones: A new class of antidiabetic drugs
30. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat
31. Rosiglitazone: No effect on erythropoiesis or premature red cell destruction
32. Rosiglitazone does not adversely affect cardiac structure or function in patients with type 2 diabetes
33. Hepatotoxicity due to troglitazone: Report of two cases and review of adverse events reported to the United States Food and Drug Administration
34. Hepatocellular injury in a patient receiving rosiglitazone. A case report
35. Rosiglitazone and hepatic failure
36. Rosiglitazone, a PPAR-gamma agonist, does not alter the pharmacokinetics of nifedipine, a cytochrome P450 3A4-substrate
37. Rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics
38. Rosiglitazone pharmacokinetics are not affected by coadministration of ranitidine
39. Coadministration of rosiglitazone and acarbose: Lack of a clinically relevant pharmacokinetic drug interaction
40. Rosiglitazone, a PPAR gamma agonist, does not alter the pharmacokinetics of oral contraceptives
41. Chronic administration of rosiglitazone does not alter the pharmacokinetics of digoxin
42. Update: Clinically significant cytochrome p450 drug interactions